AVN-101

AVN-101

AVN-101

AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it is in phase II clinical trials for these indications.[2][3][4]

See also

References

  1. ^ V. Ivachtchenko, Alexandre; A. Ivanenkov, Yan (2013). "Small Molecule 5-HT6R Ligands: A Comprehensive Insight into their Selectivity and Activity". Current Bioactive Compounds 9 (1): 64–100.  
  2. ^ a b Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews Drug Discovery 12 (9): 667–687.  
  3. ^ a b Benhamú, Bellinda; Martín-Fontecha, Mar; Vázquez-Villa, Henar; Pardo, Leonardo; López-Rodríguez, María L. (2014). "Serotonin 5-HT6Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer’s Disease". Journal of Medicinal Chemistry 57 (17): 7160–7181.  
  4. ^ AdisInsight. "AVN 101" (HTML). Retrieved 2015-06-10. 

External links

  • Pipeline - Avineuro Pharmaceuticals, Inc.
  • CNS Platform - AllaChem
  • AVN-101 - AdisInsight